Organic Active Ingredients TRIZ Cases

Sulphated polysaccharides inhibit fibrosis in eye drainage structures, reversing glaucoma root causes.

RAD1901 degrades ER alpha to overcome toxicity and resistance limits of prior endocrine therapies in epithelial ovarian cancer.

Incorporating stable 5' and 3' untranslated region elements into artificial nucleic acid molecules to increase protein production.

Pharmacological ascorbic acid generates reactive oxygen species to selectively destroy cancer cells while sparing normal tissue from chemotherapy toxicity.

A prebiotic composition using grape ferment, lactitol, and fructooligosaccharide to increase bacterial counts.

HMGB family proteins bind abnormal polyglutamine chains to prevent nuclear inclusion formation.

Acidified hypertonic saline rinse prevents halophilic organism growth through pH control, ensuring ten-week stability at 20°C.

Selective AT2R agonists resolve insufficient therapeutic effects by activating protective pathways while suppressing excessive AT1R inflammatory responses.

Replacing cyclodextrins with ethanol or propylene glycol mixtures reduces nephrotoxicity while maintaining alprostadil stability.

18-methyl-19-nor-androst-spiroether compounds modify molecular stereochemistry to enhance progesterone receptor binding affinity.

Engineered rAAV vectors carrying microRNA sponges and XIST RNA selectively silence mutant alleles to restore wild-type gene expression.

Palladium-catalyzed indazole conversion eliminates nitroaniline impurities, delivering high-purity VR1 inhibitors.

Zinc complexes convert volatile sulfur compounds into non-volatile forms, resolving the trade-off between effective odor control and tooth staining.

Indane acetic acids serve as intermediary mediators that prevent amyloid-related imaging abnormalities while maintaining antibody efficacy.

Novel adamantyl derivative inhibits DPP4 enzyme activity to attract T cells toward tumor tissues, reducing side effects while enhancing anticancer efficacy.

Viscous microemulsion gel replaces allergenic silicone to soften scars, break adhesions, and improve elasticity without occlusion.

Engineered knottin peptides bind integrin receptors to deliver nucleoside drugs directly into cancer cells.

Segmented particle systems overcome shallow penetration limits by combining surface-bound microparticles with deep-diffusing nanoparticles.

Amorphous and crystalline desvenlafaxine solid forms combine with hydroxybenzoic acid co-formers to enhance physicochemical properties.

1,3-Dioxoindene derivatives overcome poor solubility and side effects of existing antivirals to treat picornavirus infections.

Segmenting active inhibitors with removable moieties resolves solubility constraints, enabling potent Mps-1 kinase treatment.

Ingenol analogs activate protein kinase C to reactivate latent HIV reservoirs, reducing systemic inflammation and drug resistance risks.

Castor oil and dimethylsulfoxide dissolve ataluren completely, preventing precipitation and drug loss that occur in aqueous vehicles.

In vitro method determines individual HLA patterns using RNA transcript expression levels to guide therapeutic agent development.

2′ fluoro-modified RNA overcomes rapid serum degradation while maintaining Pattern Recognition Receptor activation for sustained anti-tumor immunity.

Algae-based oil with astaxanthin and hyaluronic acid improves bioavailability while addressing sustainability issues from dwindling krill supplies.

Formula 1 compounds inhibit cholangiocarcinoma growth in patients with RON mutations resistant to cetuximab.

Formula II compounds inhibit RORγ activity to reduce IL-17 levels, treating psoriasis with lower toxicity than existing immunosuppressants.

Heterocyclic compounds selectively inhibit PARP1 to target cancer cells while sparing PARP2, reducing adverse effects on hematopoiesis and spermatogenesis.

A polysaccharide matrix disperses cyclodextrin clathrates to modulate active ingredient release profiles.

Antibodies neutralize DKK1 and DKK4 to reactivate Wnt signaling, restoring osteoblastic activity while suppressing osteoclastic resorption.

Segmented CAR-T therapy delivers localized anticancer effects against claudin 18A2 while avoiding systemic side effects from interferon treatments.

N-acetylglucosamine derivatives enhance branched N-glycan levels to inhibit T cell autoimmunity without broad immunosuppression.

Acetic acid mediates derivatization while precipitation removes contaminants, preventing polymer hydrolysis during purification.

Pyrimidine compounds inhibit EGFR mutants like T790M while sparing wild-type receptors to reduce drug toxicity.

Segmented granules with a gastric-soluble subcoat prevent hydrogen bonding between oxycodone and Eudragit, stopping oxidative degradation during storage.

Acid-labile lipophilic prodrugs target brain tumors through LDL receptors, reducing systemic toxicity while maintaining plasma stability.

Intrathecal MCOPPB administration activates nociceptin receptors, reducing neuropathic pain intensity without opioid side effects.

Merges fish oil with phospholipid-bound EPA and DHA to overcome limited bioavailability of conventional omega-3 supplements.

A solute solution contacts supercritical carbon dioxide to trigger rapid nucleation and form fine solid particles.

Antibodies 515H7 and 301aE5 target CXCR4 homodimers, inducing conformational changes that inhibit X4-tropic HIV replication in PBMCs.

Organic acid and polyalcohol dissolve lidocaine in a non-aqueous patch, enabling stable 12-hour permeation without high-concentration side effects.

Formula A compounds modulate BTK kinase activity, improving complete response rates in Waldenström's macroglobulinemia treatment.

Formula I fused bicyclic diamines selectively block the ROMK channel, promoting diuresis while minimizing adverse effects on potassium levels.

Pyridazine derivatives modulate autotaxin activity, sustaining lysophosphatidic acid reduction beyond current inhibitor capabilities.

Phosphodiamide prodrugs of tenofovir bypass cellular permeability barriers to inhibit mutant HIV reverse transcriptase.

A metal salen complex binds drugs to exhibit magnetic properties for targeted delivery.

A pharmaceutical preparation containing omidenepag lowers intraocular pressure in patients with glaucoma.

Amphoteric surfactants stabilize omega-3 triglyceride emulsions for parenteral nutrition.

A solid dispersion extrudate of Compound 1 with a vinylpyrrolidinone-vinyl acetate copolymer enhances dissolution rate and oral bioavailability.

A flavonoid composition containing eriocitrin reduces inflammatory cytokine levels through synergistic NF-kB inhibition.

Benzimidazole thiophene compounds inhibit Polo-like kinase activity to treat cancers with PLK overexpression.

Lysophosphatidylcholine and TLR7/8 agonists hyperactivate dendritic cells without septic shock risk or pyroptosis.

Extracellular vesicles protect antisense oligonucleotides from degradation, improving stability and targeting efficiency for cancer treatment.

Marine copepod oil rich in wax esters selectively inhibits visceral fat accumulation and improves glucose tolerance without toxic side effects.

Segmenting the tablet into two layers resolves flowability and compressibility issues while ensuring stability through antioxidant placement.

Wnt/beta-catenin pathway inhibitors expand treatment options by enhancing peroxisome biogenesis and the interferon response.

Magnetic hyperthermia activates energy-actuatable particles within the coating, releasing localized heat to eradicate resistant biofilms on prosthetic joints.

RNAi agents reduce beta-2 microglobulin levels to treat aging-associated cognitive impairments by enhancing hippocampal-dependent cognitive function.

Sulfated hyaluronan blocks RAGE receptors to reduce inflammation without heparin bleeding risks or cross-species virus transmission.

Nitrogen-filled heads in translucent polypropylene bags prevent oxidation and subvisible particle formation without antioxidants.

Replacing hazardous acryloyl chloride with a boronic acid coupling and elimination sequence yields stable Sotorasib polymorphs without flammability risks.

A nutritional composition combines 6'-sialyllactose and lacto-N-tetraose to activate the GPR35 receptor.

Oxa spiro derivatives minimize beta-arrestin pathway interaction to reduce respiratory depression and tolerance while maintaining receptor sensitivity.

Optimized solriamfetol dose escalation scheme minimizes adverse effects in renally impaired subjects.

A foamable ruxolitinib composition delivers the active ingredient to the scalp via a pressurized container.

1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol suppresses brain atrophy in Alzheimer's disease patients.

Pairs anti-CD123 antibody-drug conjugate with PARP inhibitor to overcome resistance in relapsed acute myeloid leukemia.

Novel TRPM8 receptor antagonists target cold-sensing channels with high molecular selectivity, reducing interference with other ion systems.

Bumetanide blocks the NKCC1 co-transporter to reduce intracellular chloride concentration in neurons.

Combination therapy targeting primary and secondary pathways prevents refractory cancer development during hormone depletion treatment.

New urea derivatives lower blood glucose levels while minimizing side effects.

Thiophosphate nucleosides treat hepatitis C infections by modifying chemical structures to reduce host toxicity while maintaining antiviral efficacy.

A pharmaceutical composition containing hyaluronic acid and chondroitin sulfate for bladder instillation.

Formula I compounds inhibit LPAR1 activity through specific receptor binding, resolving selectivity and metabolic stability trade-offs.

CRISPR-modified Lactobacillus crispatus treats inflammatory skin conditions by reducing pathogenic loads without antibiotic resistance.

Dual inhibition of JNK and PDGFR pathways overcomes monotherapy limitations to effectively suppress malignant peripheral nerve sheath tumor progression.

ADPR inhibits Sirt6 and boosts Pax6 and p53 activity to manage RNA virus infections.

Combining trastuzumab with small molecule tyrosine kinase inhibitors overcomes resistance to traditional therapies by blocking key survival pathways.

Deuterium-modified brigatinib derivatives enhance oral bioavailability and pharmacokinetic properties through structural parameter changes.

Low-dose selective p38 MAPK inhibitor reduces amyloid plaque burden while avoiding neuroinflammatory side effects.

Methocinnamox binds functionally to mu-opioid receptors as a pseudo-irreversible antagonist.

A nutritional composition combining sialyllactose, LCPUFAs, and LGG probiotics to support postpartum maternal health.

Doping organic agents within metal carbonate crystal lattices enables controlled drug release upon dissolution.

Prebiotic matrices shield probiotics from gastric acid, reducing microbial loss while expanding gut flora coverage.

Combining feverfew, white willow, and magnesium extracts creates a synergistic food supplement formulation.

A dual channel ultrasonic spray gun atomizes two solutions simultaneously to fabricate multilayered microstructures.